Related Experiment Video
Updated: Dec 26, 2025

Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I
Joseph Kuo1, Shih-Ku Lin2,3
1Department of Psychiatry, Camillians Saint Mary's Hospital Luodong, Yilan, Taiwan.
Abstract:
Extended-release injectable (ERI) aripiprazole is indicated for schizophrenia and maintenance monotherapy of bipolar I disorder. Clinical trials of aripiprazole failed to exhibit efficacy in the treatment of bipolar depression. It has been suggested that relatively high doses, rapid titration of dose, a high dropout rate, and a high placebo effect might be the reasons of its ineffectiveness. Here, we report a case of a 39-year-old woman with bipolar depression who was successfully treated with ERI aripiprazole.
Related Concept Videos
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Bipolar Disorder
Psychosis and Antipsychotic Drugs: Overview
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...

